MAP2K7 and Miyoshi myopathy: Although there is no clinical trial underway specifically evaluating the safety and efficacy of combination therapy of BRAF inhibitor plus MEK inhibitor in MM, a retrospective study in Japan showed that MM/AM and CM exhibited similar response rates to combined BRAF and MEK suppression (64.3% vs 76.5%) (139), suggesting the potential efficiency of dual repression of BRAF and MEK in MM.